Promising novel therapies are on the horizon within the field of chronic lymphocytic leukemia (CLL). Here, Jennifer Woyach, MD, of the Ohio State University Comprehensive Cancer Center, Columbus, OH, discusses an exciting array of therapeutics which are being utilized in clinical practice: BTK, PI3K and BCL-2 inhibitors. In addition, Dr Woyach explores the use of immunotherapy ventures, such as CAR T cells, speculating upon the efficacy surrounding combination treatments. Moreover, she explores the possibility of utilizing up-and-coming therapeutics, which are currently in early clinical trials, such as reversable BTK inhibitors and bromodomain inhibitors. Dr Woyach finally touches upon some challenges faced within the field, namely patient discontinuation of ibrutinib and venetoclax, when patients should be referred for bone marrow transplant, and the role of Richter transformation in relapse. This video was recorded at the British Society for Haematology (BSH) 2018 Annual Meeting, in Liverpool, UK.